Imaging Agent from Expert BioMed for Early Detection of Alzheimer's Disease

FLORIDA -

FLORIDA – Expert BioMed, Inc. (EBMed), a product-focused molecular imaging company, and PET Laboratory of Massachusetts General Hospital/Harvard University (MGH), a world leader in the diagnostic imaging pharmaceutical field develop EBMed’s 11C-EBM1/TN compound, a molecular imaging agent that targets damaged neurons in the brain. When used with positron emission tomography (PET) imaging, the EMB1/TN compound may enable earlier and more accurate diagnosis of Alzheimer’s Disease (AD), a disease that currently affects an estimated 5 million Americans and is expected to potentially affect up to 16 million Americans by the year 2050 (www.alz.org).

“We are very pleased that MHG is committed to the field of molecular imaging and to the development of 11C-EBM1/TN,” said Elena Paley, PhD, President and CEO of EBMed. “This is an endorsement of both the potential clinical value of 11C-EBM1/TN as well as our product pipeline of molecular imaging compounds for early diagnosis of AD, Parkinson’s disease (PD) and Dementia with Lewy Bodies (DLB). To have a world-class Medical Center like MGH invest in this field will only accelerate the development of new products like 11C-EBM1/TN to the benefit of both physicians and AD patients in the future.”

11C-EBM1/TN is one of a series of novel compounds discovered in the laboratory of Dr. Elena Paley and exclusively licensed to EBMed for development and commercialization. EBMed plans to enter into an exclusive option agreement with the large pharmaceutical company for the development of 11C-EBM1/TN and related compounds for positron emission tomography (PET) imaging of Alzheimer’s disease.

New treatment methods for slowing or reversing the neurodegeneration in the brains of people with Alzheimer’s disease are the subject of intensive clinical research by many large pharmaceutical companies as well as the National Institutes of Health. It is anticipated that molecular imaging agents such as those being developed by EBMed may help in identifying Alzheimer’s patients who will benefit from these emerging treatments.

About EBMed
Expert BioMed, Inc. is a product-focused molecular imaging company which is developing novel diagnostic imaging agents to enable the early diagnosis, treatment selection and therapeutic monitoring of major medical disorders. The company is a pioneer in the development of molecular imaging agents for Alzheimer’s disease. EBMed’s compounds may enable the earlier diagnosis of Alzheimer’s disease and also allow researchers to better evaluate therapeutic drug candidates for the prevention or reversal of neurodegeneration in the brain. EBMed’s technology can be used with a variety of imaging technologies such as positron emission tomography (PET) and magnetic resonance imaging/spectroscopy (MRI/MRS) and is currently being tested in the preclinical studies. EBMed has a number of other PET agents for Alzheimer’s disease for clinical trials in the United States. Recent research has also shown that imaging with 11C-EBM1/TN may be useful in monitoring the functional viability of β-islet cells of the pancreas, which is a major issue related to the status and progression of diabetes mellitus. The 11C-EBM1/TN imaging program has grown out of a close collaboration with Dr Anna-Liisa Brownell of the University of Harvard as well as the MGH.